Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
IPO Year: 2000
Exchange: NASDAQ
Website: cgen.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/13/2025 | $4.00 | Outperform | Oppenheimer |
| 8/5/2022 | $2.00 | Buy → Hold | Jefferies |
| 2/25/2022 | $17.00 → $14.00 | Outperform | Oppenheimer |
| 2/25/2022 | $16.00 → $9.00 | Outperform | SVB Leerink |
Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025Recruitment ongoing in the first in human Phase 1 trial of GS-0321 (previously COM503), a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca expanded their rilvegostomig program to ten Phase 3 trials across lung, gastrointestinal and endometrial cancers and plans to share early data for rilvegostomig at ASCOSolid financial position with cash runway expected to fund operations into 2027Key leadership transitions to take effect in September 2025HOLON, Israel, May 19, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage ca
HOLON, Israel, May 5, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its first quarter 2025 financial results on Monday, May 19, 2025, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is located at the following link. Following
In the news release, Compugen Reports Fourth Quarter and Full Year 2024 Results, issued 04-Mar-2025 by Compugen Ltd. over PR Newswire, in the Conference Call and Webcast Information section, the link to the webcast should be "https://veidan.activetrail.biz/compugenq4-2024". The complete, corrected release follows: Compugen Reports Fourth Quarter and Full Year 2024 Results Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibodyOn track to initiate a randomized adaptive platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer, scheduled to start in Q2 2025The first patient was dosed in Q
Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibodyOn track to initiate a randomized adaptive platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer, scheduled to start in Q2 2025The first patient was dosed in Q1 2025 in the first in human Phase 1 solid tumor trial of GS-0321 (previously COM503), a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca reported promising rilvegostomig data in 2024, expanded the rilvegostomig program to seven Phase 3 trials across lung and gastrointestinal cancers and plans to share early data for rilvegostomig in combina
HOLON, Israel, Feb. 18, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that it will release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, before the U.S. financial markets open. Management will host a conference call and webcast to review the financial results and provide a corporate update at 8:30 am ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following lin
Clinical data presented at SITC 2024 demonstrated COM701 (anti-PVRIG) mediated anti-tumor activity with durable responses and good tolerability profile in tumors typically not responding to immunotherapy, aligned with previous data presented by the CompanyPlans to initiate, in Q2 2025, an adaptive platform trial in patients with relapsed platinum sensitive ovarian cancer in the maintenance setting, to evaluate single agent COM701 and future combinations representing an unmet need and regulatory and commercial opportunityOn track to initiate Phase 1 trial evaluating COM503 (anti-IL18BP) in solid tumors in Q4 2024Partner AstraZeneca reported encouraging rilvegostomig data at WCLC and ESMO 2024
HOLON, ISRAEL, Nov. 5, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that data supporting the anti-tumor activity and safety profile of the triple combination COM701, COM902 and pembrolizumab in advanced heavily pre-treated patients with platinum resistant ovarian cancer (PROC) has been published as an abstract released by the Society for Immunotherapy of Cancer (SITC). This data and additional clinical data will be presented by Oladapo Yeku, M.D., Ph.D., FACP, Assistant Professor of Medicine, Harvard Medical School, and Director of Translational Research, Gynecolog
HOLON, Israel, Oct. 29, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that it will release its third quarter 2024 financial results on Tuesday, November 12, 2024, before the U.S. financial markets open. Management will host a conference call and webcast to review the financial results and provide a corporate update at 8:30 am ET. As part of the update, management will discuss Compugen's data that will have been presented at the Annual Meeting of the Society for Immunotherapy of Cancer, being held on November 8-10, 2024. To access the live conference call by telepho
FDA clearance of COM503 IND in July 2024 triggered a $30 million milestone payment from Gilead On track to present data from COM701 + COM902 + pembrolizumab, platinum resistant ovarian cancer study in Q4 2024Partner, AstraZeneca, advanced development of rilvegostomig, and provided a non-risk adjusted peak year revenue target of over $5 billion, reflecting the potential of the asset. Compugen is eligible for future milestones and mid-single-digit tiered royalty payments, presenting a significant potential revenue source for the CompanySolid balance sheet with cash runway expected to fund operations into 2027HOLON, Israel, Aug. 6, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a
HOLON, Israel, July 23, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its second quarter 2024 financial results on Tuesday, August 6, 2024, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following link. Following the
6-K - COMPUGEN LTD (0001119774) (Filer)
6-K - COMPUGEN LTD (0001119774) (Filer)
20-F - COMPUGEN LTD (0001119774) (Filer)
6-K - COMPUGEN LTD (0001119774) (Filer)
SCHEDULE 13G/A - COMPUGEN LTD (0001119774) (Subject)
6-K - COMPUGEN LTD (0001119774) (Filer)
6-K - COMPUGEN LTD (0001119774) (Filer)
6-K - COMPUGEN LTD (0001119774) (Filer)
6-K - COMPUGEN LTD (0001119774) (Filer)
6-K - COMPUGEN LTD (0001119774) (Filer)
Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025Recruitment ongoing in the first in human Phase 1 trial of GS-0321 (previously COM503), a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca expanded their rilvegostomig program to ten Phase 3 trials across lung, gastrointestinal and endometrial cancers and plans to share early data for rilvegostomig at ASCOSolid financial position with cash runway expected to fund operations into 2027Key leadership transitions to take effect in September 2025HOLON, Israel, May 19, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage ca
Anat Cohen-Dayag, Ph.D., appointed as Executive Chair of the Board of DirectorsEran Ophir, Ph.D., appointed as President and Chief Executive Officer and will join the Board of DirectorsPaul Sekhri to step down as Chair of the Board of DirectorsHOLON, Israel, May 13, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced key leadership transitions to take effect in September 2025 following the Annual General Meeting. Anat Cohen-Dayag, Ph.D., currently President and Chief Executive Officer will assume the newly created role of Executive Chair of the Board of Directors, subject
HOLON, Israel, May 5, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its first quarter 2025 financial results on Monday, May 19, 2025, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is located at the following link. Following
HOLON, Israel, March 26, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in the following upcoming virtual investor conferences in April 2025: H.C. Wainwright 2nd Annual AI Based Drug Discovery & Development ConferenceDate: Wednesday, April 2, 2025Format: Fireside chat and 1x1 meetingsFireside chat time: 9:30 am ET 24th Annual Needham Virtual Healthcare ConferenceDate: Monday, April 7, 2025Format: Fireside chat and 1x1 meetingsFireside chat time: 8:00 am ET Stifel's 2025 Virtual Targeted Oncology ForumDate: Wednesday, April 9, 2025Form
In the news release, Compugen Reports Fourth Quarter and Full Year 2024 Results, issued 04-Mar-2025 by Compugen Ltd. over PR Newswire, in the Conference Call and Webcast Information section, the link to the webcast should be "https://veidan.activetrail.biz/compugenq4-2024". The complete, corrected release follows: Compugen Reports Fourth Quarter and Full Year 2024 Results Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibodyOn track to initiate a randomized adaptive platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer, scheduled to start in Q2 2025The first patient was dosed in Q
Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibodyOn track to initiate a randomized adaptive platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer, scheduled to start in Q2 2025The first patient was dosed in Q1 2025 in the first in human Phase 1 solid tumor trial of GS-0321 (previously COM503), a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca reported promising rilvegostomig data in 2024, expanded the rilvegostomig program to seven Phase 3 trials across lung and gastrointestinal cancers and plans to share early data for rilvegostomig in combina
HOLON, ISRAEL , March 3, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference, Miami Beach, Florida, on Tuesday, March 11, 2025 at 8:00 AM ET. A live webcast of the presentation will be available on the events page of the Investor Relations section of Compugen's website at www.cgen.com. A replay will be available following the live event. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predicti
Gene structure information identified by combining Compugen's AI/ML predictive computational discovery platform, Unigen™ with Ultima's UG 100™ sequencing platform to better understand tumor biology and immune regulationLeveraging Compugen's computational analytical tools uncovered high consistency in single-cell expression levels across Ultima's UG 100 sequencing platform, offering a potential advantage for demarcation of transcript termination.Research presented at Advances in Genome Biology and Technology (AGBT) 2025 General MeetingHOLON, Israel, Feb. 26, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computation
Announcement reflects company's commitment to augment Board of Directors with industry-experienced executives from both the government and software sectors Cognyte Software Ltd. (NASDAQ:CGNT) ("Cognyte"), a global leader in investigative analytics software, today announced the appointment of two new members to its Board of Directors. Matthew O'Neill and Nurit Benjamini will join the board on March 1, 2025, and March 31, 2025, respectively, reflecting the company's commitment to add independent directors from the government and software sectors. Richard Nottenburg will be stepping down from his board position effective March 31, 2025. Having served with the United States Secret Service f
HOLON, Israel, Feb. 18, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that it will release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, before the U.S. financial markets open. Management will host a conference call and webcast to review the financial results and provide a corporate update at 8:30 am ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following lin
Oppenheimer initiated coverage of Compugen with a rating of Outperform and set a new price target of $4.00
Jefferies downgraded Compugen from Buy to Hold and set a new price target of $2.00
Oppenheimer reiterated coverage of Compugen with a rating of Outperform and set a new price target of $14.00 from $17.00 previously
SVB Leerink reiterated coverage of Compugen with a rating of Outperform and set a new price target of $9.00 from $16.00 previously
SVB Leerink reiterated coverage of Compugen with a rating of Outperform and set a new price target of $16.00 from $19.00 previously
SC 13G/A - COMPUGEN LTD (0001119774) (Subject)
SC 13G/A - COMPUGEN LTD (0001119774) (Subject)
SC 13G/A - COMPUGEN LTD (0001119774) (Subject)
SC 13G/A - COMPUGEN LTD (0001119774) (Subject)
SC 13G - COMPUGEN LTD (0001119774) (Subject)
SC 13G/A - COMPUGEN LTD (0001119774) (Subject)
SC 13G/A - COMPUGEN LTD (0001119774) (Subject)
SC 13G/A - COMPUGEN LTD (0001119774) (Subject)
Announcement reflects company's commitment to augment Board of Directors with industry-experienced executives from both the government and software sectors Cognyte Software Ltd. (NASDAQ:CGNT) ("Cognyte"), a global leader in investigative analytics software, today announced the appointment of two new members to its Board of Directors. Matthew O'Neill and Nurit Benjamini will join the board on March 1, 2025, and March 31, 2025, respectively, reflecting the company's commitment to add independent directors from the government and software sectors. Richard Nottenburg will be stepping down from his board position effective March 31, 2025. Having served with the United States Secret Service f
HOLON, Israel, May 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of David Silberman as its new Chief Financial Officer effective August 15, 2024, taking over from Alberto Sessa who will depart Compugen on the same day. David will join Compugen from Oramed Pharmaceuticals Inc., where he served as Chief Financial Officer. "I am excited to welcome David to Compugen and believe his experience and insights will make him a pivotal additio
HOLON, Israel, Feb. 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024. Michelle will succeed Henry Adewoye, M.D., who is leaving Compugen to pursue other opportunities effective February 29, 2024, after 6 years with Compugen. "I am delighted that Michelle will join the management team as Chief Medical Officer at a very exciting time for Compugen," said Anat Coh
HOLON, Israel, Sept. 12, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Alberto Sessa has been appointed Chief Financial Officer (CFO) and member of the management team. Alberto will join Compugen on November 1, 2022. "I am delighted to have a financial executive of Alberto's expertise and experience join Compugen and strengthen our management team," said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen. "His extensive experience and track record in leading financing, investor relations, M&A, and business development transactions and providing stra
HOLON, Israel, Feb. 24, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), ("Compugen", the "Company"), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today the appointment of Mathias Hukkelhoven, Ph.D., formerly Senior Vice President, Global Regulatory, Safety & Biometrics at Bristol Myers Squibb, to its Board of Directors effective March 1, 2022. In addition, the Company announced that Dr. Jean-Pierre Bizzari will retire from its Board of Directors. "I am delighted to welcome Math to Compugen's Board," said Paul Sekhri, Chairman of the Board. "His considerable experience in immuno-oncology drug development including involvement in five b